I. Introduction
Ulinastatin, a naturally occurring protease modulator generated from human urine, has been used for decades to treat inflammatory disorders like sepsis, acute pancreatitis, and organ failure. [Wei, 2021] [Horváth, 2022] [Wang, 2019] [Atal, 2016] Its main activity is to block enzymes such as trypsin, chymotrypsin, elastase that cause tissue damage and inflammation, while conversely it activates thermolysin and liberase activity, so it is likely to have multimodal activity. [Umeadi, 2008] [Linder, 2014] Ulinastatin has demonstrated considerable therapeutic effects in the treatment of inflammatory illnesses in Japan, China, and India. This article investigates the role of ulinastatin in these three nations, emphasizing its use, regulatory landscape, and therapeutic results.
II. Japan: Pioneers in Ulinastatin Therapy
In Japan, ulinastatin has been in clinical usage since 1985, when Mochida introduced Miraclid®, the world's first ulinastatin preparation. [Mochida, n.d.] Japan is regarded as a pioneer in the therapeutic use of ulinastatin, notably in the treatment of acute pancreatitis, sepsis/systemic inflammatory response syndrome (SIRS), Stevens-Johnson syndrome, and Kawasaki disease. [Inamo, 2002] [Kanai, 2011] [Zhang, 2022]
III. Regulatory Approval and Usage
The Japanese Pharmaceuticals and Medical Devices Agency (PMDA) authorized ulinastatin to treat a variety of inflammatory diseases. It is frequently used in emergency rooms, notably for acute pancreatitis, and to avoid organ failure in sepsis patients. Its clinical applicability is well-established in Japan, and it is used extensively in intensive care units (ICUs) throughout the country. [Yamazaki, 2011]
Clinical Outcomes
Several clinical trials in Japan have demonstrated the efficacy of ulinastatin in reducing mortality and improving clinical outcomes in patients with severe inflammatory conditions. For example, in a randomized clinical study, patients on ulinastatin had significantly lower blood and drain amylase levels than those in the placebo group. Ulinastatin dramatically reduced the frequency of hyperamylasemia and postoperative pancreatitis. Although there was no significant difference in the incidence of pancreatic fistula between the groups, the data indicated that prophylactic ulinastatin medication lowered the risk of postoperative pancreatitis. [Uemura, 2008]
Additionally, ulinastatin has been explored in the context of cardiopulmonary bypass surgeries, where it has been shown to reduce inflammatory markers and improve postoperative outcomes. This makes it a valuable tool in reducing inflammation-related complications during and after major surgeries in Japan. [Sugita, 2002]
China: Expanding Indications for Ulinastatin
China has played a vital role in the mass manufacture and clinical application of ulinastatin. The medication is widely utilized in the treatment of sepsis, acute respiratory distress syndrome (ARDS), and multiple organ dysfunction syndrome (MODS), especially in ICUs. [Zhang, 2019]. Furthermore, a clinical investigation in China demonstrated that high-dose ulinastatin was effective against COVID-19. [Huang, 2022]. The National Medical Products Administration (NMPA) of China authorized ulinastatin for clinical usage after studying its anti-inflammatory and organ-protective properties. [Wang, 2019]
Sepsis and Acute Pancreatitis Management
Sepsis, a life-threatening illness caused by an excessive immunological response to infection, is still a huge healthcare burden in China. Ulinastatin has gained popularity as an additional therapy for sepsis because it helps decrease the overwhelming inflammatory response that defines sepsis. In a large multicenter study, patients who got ulinastatin in conjunction with standard sepsis care had considerably reduced fatality rates than those who received standard therapy alone. [Wang, 2019]
In China, ulinastatin is also often used to treat acute pancreatitis. Ulinastatin has been found in studies to considerably lower blood levels of inflammatory indicators such as C-reactive protein and pro-inflammatory cytokines, resulting in better clinical outcomes in patients with severe acute pancreatitis. [Wang, 20...
(All Rights Reserved)